Intercept Pharmaceuticals Announces Completion of Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial

[at noodls] – NEW YORK, Dec. 19, 2012 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel … more

View todays social media effects on ICPT

View the latest stocks trending across Twitter. Click to view dashboard

See who Intercept is hiring next, click here to view